Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction
Lubov A. Ezerskiy, … , Randall J. Bateman, Timothy M. Miller
Lubov A. Ezerskiy, … , Randall J. Bateman, Timothy M. Miller
Published December 7, 2021
Citation Information: JCI Insight. 2022;7(1):e152012. https://doi.org/10.1172/jci.insight.152012.
View: Text | PDF
Research Article Neuroscience

Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction

  • Text
  • PDF
Abstract

The protein tau and its isoforms are associated with several neurodegenerative diseases, many of which are characterized by greater deposition of the 4-repeat (4R) tau isoform; however, the role of 4R tau in disease pathogenesis remains unclear. We created antisense oligonucleotides (ASOs) that alter the ratio of 3R to 4R tau to investigate the role of specific tau isoforms in disease. Preferential expression of 4R tau in human tau–expressing (hTau-expressing) mice was previously shown to increase seizure severity and phosphorylated tau deposition without neuronal or synaptic loss. In this study, we observed strong colocalization of 4R tau within reactive astrocytes and increased expression of pan-reactive and neurotoxic genes following 3R to 4R tau splicing ASO treatment in hTau mice. Increasing 4R tau levels in primary astrocytes provoked a similar response, including a neurotoxic genetic profile and diminished homeostatic function, which was replicated in human induced pluripotent stem cell–derived (iPSC-derived) astrocytes harboring a mutation that exhibits greater 4R tau. Healthy neurons cultured with 4R tau–expressing human iPSC–derived astrocytes exhibited a higher firing frequency and hypersynchrony, which could be prevented by lowering tau expression. These findings support a potentially novel pathway by which astrocytic 4R tau mediates reactivity and dysfunction and suggest that astrocyte-targeted therapeutics against 4R tau may mitigate neurodegenerative disease progression.

Authors

Lubov A. Ezerskiy, Kathleen M. Schoch, Chihiro Sato, Mariana Beltcheva, Kanta Horie, Frank Rigo, Ryan Martynowicz, Celeste M. Karch, Randall J. Bateman, Timothy M. Miller

×

Figure 1

4R tau expression in astrocytes leads to a reactive phenotype in vivo.

Options: View larger image (or click on image) Download as PowerPoint
4R tau expression in astrocytes leads to a reactive phenotype in vivo.
(...
(A, D, and G) 4R tau, (B, E, and H) glial fibrillary acidic protein (GFAP), and (C, F, and I) merged representative images of the dentate gyrus of the hippocampus, contralateral to ASO injection, in hTau mice treated with control ASO, 4R to 3R tau splicing ASO, or 3R to 4R tau splicing ASO. Scale bar: 50 μm. (J) Percentage of the total visual field that had 4R tau colocalized with GFAP. Data are shown as mean ± SEM; 2-way ANOVA with Tukey’s multiple comparisons; n = 5–6 mice per treatment, ****P < 0.0001. (K) Expression of select pan-reactive (Gfap, Vimentin, and Serpina3n), neurotoxic (C3, Srgn, Gbp2, Serping1, and Fbln5), and neuroprotective (S100a10 and Cd109) genes in hTau mouse brain lysates after control, 4R to 3R tau splicing, or 3R to 4R tau splicing ASO treatment measured by qRT-PCR. Data are normalized to Gapdh relative to control ASO levels and shown as mean ± SEM; 2-way ANOVA with Tukey’s multiple comparisons; n = 5–6 mice per treatment, *P < 0.05, ***P < 0.001, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts